Patents Assigned to SCIENTIFIQUE (CNRS)
-
Publication number: 20220267289Abstract: A compound of formula (I): or pharmaceutically acceptable enantiomer, salt or solvate thereof, or a mixture thereof, the ring A, and the substituents Z, Y and R1 being as defined herein.Type: ApplicationFiled: June 1, 2020Publication date: August 25, 2022Applicants: UNIVERSITE GRENOBLE ALPES, CNRS - CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE CLAUDE BERNARD LYON 1Inventors: Ahcène BOUMENDJEL, Pierre FALSON, Alexis MORENO, Basile PERES, Emile ROUSSEL
-
Publication number: 20220266505Abstract: The method for manufacturing a three-dimensional object or for modifying the surface state of a preformed object by local polymerisation of monomers or oligomers, the polymerisation being initiated by mono-photon or multi-photon absorption in an area to be polymerised, includes: —introducing into a vessel with light-transparent walls a reaction medium comprising polymerisable monomers or oligomers, a polymerisation inhibitor, an indicator of the amount of the inhibitor and a photochemical polymerisation initiator; —initiating the polymerisation of the monomers or oligomers; —indicating the amount of inhibitor present in the reaction medium; —controlling the amount of light emitted by the irradiation system relative to the amount of inhibitor indicated by the indicator; and —switching to a following zone to be polymerised by moving the object and/or the focused light beam.Type: ApplicationFiled: July 22, 2020Publication date: August 25, 2022Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE D'AIX-MARSEILLE (AMU), ECOLE CENTRALE DE MARSEILLEInventors: Claude Amra, Jean-Claude André, Laurent Gallais-During, Myriam Zerrad
-
Patent number: 11421277Abstract: The present invention relates to a method for predicting the risk of having the CLAD in a subject by measuring the expression level of TCL1A in a biological sample obtained from said subject. Inventors have used a large-scale gene expression profiling of whole blood cells to identify early biomarkers of BOS. Microarray experiments performed from 80 patients (40 stable (STA) and 40 BOS) identified 47 genes differentially expressed between STA and BOS recipients. An independent set of patients (13 STA, 11 BOS) was then used for external validation by qPCR. T-cell leukemia/lymphoma protein 1A (TCL1A) gene was identified and validated as a predictive marker of BOS more than 6 months before diagnosis with area under curve of 0.77. Accordingly, the invention relates to a method for predicting the risk of having the chronic lung allograft dysfunction (CLAD) and to a method for preventing the risk of having CLAD by administering immunosuppressive drugs.Type: GrantFiled: June 26, 2018Date of Patent: August 23, 2022Assignees: INSERM (INSTITUTE NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE NANTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CENTRE HOSPITALIER UNIVERSITAIRE DE NANTESInventors: Richard Danger, Sophie Brouard, Pierre-Joseph Royer, Antoine Magnan
-
Patent number: 11424590Abstract: According to one aspect, a few-mode amplifying fiber in a given spectral band of use is provided. The few-mode amplifying fiber comprises a cladding having a given refractive index (n0) and at least one core of refractive index and of dimensions suited to the propagation of a finite number of spatial modes in the spectral band of use of the fiber, a spatial propagation mode corresponding to a channel for transporting information. The core comprises a first solid material having a given first refractive index (n1) strictly greater than the refractive index of the cladding (n0), and, within said first material, inclusions spatially separated from one another, formed by longitudinal bars comprising a second solid material having a second refractive index (n2) strictly greater than the first refractive index (n1), at least one of said inclusions being actively doped.Type: GrantFiled: June 29, 2018Date of Patent: August 23, 2022Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE LILLEInventors: Jean-Baptiste Trinel, Guillaume Le Cocq, Laurent Bigot, Géraud Bouwmans
-
Publication number: 20220257671Abstract: Recombinant, alive and metabolically active bacteria including a heterologous prokaryotic biomineralized ferritin. In particular, the inventors have shown that naturally non-magnetic Escherichia coli may be engineered to become magnetic by the expression and the biomineralization of the ferritin of Pyrococcus furiosus. Moreover, the inventors have shown that a fixed number of magnetic E. coli strains keep their magnetic properties through cell division by asymmetrical division. The inventors have also shown that magnetic bacteria according to the invention may be of use in both non-therapeutic and therapeutic uses, such as, e.g., the biosensing of target substance, the depollution of complex environments, the display of antibodies, nanobodies and antigens, the delivery of therapeutic substance to target cells, the targeting and infection of target cells.Type: ApplicationFiled: July 24, 2020Publication date: August 18, 2022Applicants: PARIS SCIENCES ET LETTRES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, SORBONNE UNIVERSITE, MUSÉUM NATIONAL D'HISTOIRE NATURELLE (MNHN)Inventors: Zoher GUEROUI, Mary AUBRY, Wei-An WANG, François GUYOT
-
Publication number: 20220263109Abstract: Disclosed is a cell comprising an anode, a cathode and a membrane located between the anode and the cathode, wherein the membrane comprises an aqueous medium and a film comprising amyloid fibers. The invention further relates to said film, stacks of said cells, an electrolyte membrane, and the use of these various devices.Type: ApplicationFiled: July 29, 2020Publication date: August 18, 2022Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ GRENOBLE ALPES, COMMISSARIAT À L'ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVESInventors: Alan LE GOFF, Yannig NEDELLEC, Patrice RANNOU, Vincent FORGE, Michael HOLZINGER
-
Patent number: 11414398Abstract: Disclosed are organic cation transporters (OCTs) inhibitors of Formula (A), as well as their pharmaceutically acceptable tautomers, salts or solvates. Also disclosed are pharmaceutical compositions including such OCTs inhibitor of Formula (A) and their use for treating and/or preventing mood-related disorders such as depressive disorders.Type: GrantFiled: July 13, 2018Date of Patent: August 16, 2022Assignees: SORBONNE UNIVERSITÉ, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITÉ PARIS CITÉInventors: Sophie Gautron, Nicolas Pietrancosta, Francine Acher, Laetitia Chausset-Boissarie
-
Patent number: 11414516Abstract: 1) Hydrocarbon-based copolymer comprising two end groups preceded by an ester function and chosen from a 2-oxo-1,3-dioxolan-4-yl (or cyclocarbonate), a dithiocyclocarbonate, an exo-vinylene cyclocarbonate and a 2-oxo-1,3-dioxolen-4-yl, the main chain of which comprises units (I) and (II) in which R0 is notably a methyl radical; and the number-average molecular mass Mn of which is between 400 and 100 000 g/mol. 2) Process for preparing said copolymer, comprising: (i) a step of heating a statistical bipolymer A chosen from a poly(butadiene-isoprene), a poly(butadiene-myrcene) and a poly(butadiene-farnesene); and then (ii) a step of heating the product formed, in the presence of a chain-transfer agent. 3) Use as adhesive, as a mixture with an amine compound comprising at least two amine groups.Type: GrantFiled: September 27, 2018Date of Patent: August 16, 2022Assignees: BOSTIK SA, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE RENNES 1Inventors: Guillaume Michaud, Stephane Fouquay, Frederic Simon, Sophie Guillaume, Jean-Francois Carpentier, Cyril Chauveau
-
Patent number: 11414649Abstract: The invention relates to a method for reprogramming cells from aged donors or senescent cells to pluripotent cells that have lost marks of senescence. In particular, the invention relates to an ex vivo method for preparing induced pluripotent stem cells (iPSCs) from a target cell population comprising cells from aged donors or senescent cells, said method comprising the steps of culturing said target cell population under appropriate conditions for reprogramming said cells into iPSCs, wherein said appropriate conditions comprises increasing expression in said target cells, of at least the following reprogramming factors: Oct4, Klf4, Sox2, c-Myc, Lin28 and, optionally Nanog.Type: GrantFiled: December 5, 2019Date of Patent: August 16, 2022Assignees: INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE MONTPELLIER I, UNIVERSITE MONTPELLIER IIInventors: Alexandre Prieur, Ollivier Milhavet, Jean-Marc Lemaitre, Laure Lapasset
-
Patent number: 11417453Abstract: The present invention relates to an electronic device including an input and an output, the device generating an output voltage when the input of the device is supplied, the device comprising: a conversion unit converting a spin current into a charge current having an amplitude and a sign, a spin current application unit applying a spin current to the conversion unit, a ferroelectric layer, which has a ferroelectric polarization and is arranged such that the ferroelectric polarization controls at least one among the amplitude and the sign of the charge current, and an electric field application unit suitable for applying an electric field to the ferroelectric layer to control the ferroelectric polarization.Type: GrantFiled: December 27, 2019Date of Patent: August 16, 2022Assignees: THALES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, COMMISSARIAT À L'ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVESInventors: Manuel Bibes, Laurent Vila, Jean-Philippe Attané, Paul Noël, Diogo Castro Vaz
-
Publication number: 20220251564Abstract: A p16INK4a inhibitor, a composition that includes the p16INK4a inhibitor, or a pharmaceutical composition that includes the p16INK4a inhibitor, for use in the prevention and/or the treatment of Huntington's disease, wherein the p16INK4a inhibitor is a nucleic acid or a peptide, a small compound molecule or a marketed drug.Type: ApplicationFiled: April 17, 2020Publication date: August 11, 2022Applicants: SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, BUCK INSTITUTE FOR RESEARCH ON AGINGInventors: Christian NERI, Francesca FARINA, Jessica VOISIN, Lisa ELLERBY
-
Publication number: 20220251730Abstract: A method for producing at least one nitride layer includes providing a stack having a plurality of pillars extending from a substrate of the stack. Each pillar includes at least a crystalline section and a summit having a summit surface area The method also includes growing by epitaxy a crystallite from the summit of some the plurality of pillars and continuing the epitaxial growth of the crystallites until the crystallites supported by the pillars coalesce. The plurality of pillars includes at least one retention pillar and separation pillars. The pillars are configured so that once the nitride layer is formed, the at least one retention pillar retains the nitride layer and some of the separation pillars can fracture.Type: ApplicationFiled: December 22, 2021Publication date: August 11, 2022Applicants: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE GRENOBLE ALPESInventors: Matthew CHARLES, Guy FEUILLET, Roy DAGHER
-
Publication number: 20220251232Abstract: Novel anti-CD25 antibodies and antigen-bind fragments thereof that do not inhibit the binding of interleukin-2 (IL-2) to CD25, and the use thereof for treating cancer or an infectious disease. Also, fusion proteins including the antibodies and antigen-bind fragments, nucleic acids encoding the antibodies and antigen-bind fragments, and an expression vectors including the nucleic acids. Further, pharmaceutical compositions including the fusion proteins or the antibodies and antigen-bind fragments.Type: ApplicationFiled: May 20, 2020Publication date: August 11, 2022Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ D'AIX MARSEILLE, UNIVERSITE DE PARIS, ALDERAAN BIOTECHNOLOGY, UNIVERSITE PARIS EST CRETEIL VAL DE MARNEInventors: Daniel OLIVE, Armand BENSUSSAN, Jérôme GIUSTINIANI, Arnaud FOUSSAT
-
Patent number: 11408771Abstract: A method for constructing a colour space specific to an individual viewing a colour image on a display device, including at least the following steps: a first step of measuring an emitted spectral radiance; a second step of constructing a Euclidean colour space of the lights emitted by the display device; a third step of measuring, by computer, a luminance vector field perceived by the individual; a fourth step of constructing a model corresponding to the individual's perception of the colours.Type: GrantFiled: August 2, 2019Date of Patent: August 9, 2022Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE GRENOBLE ALPESInventors: David Alleysson, David Meary
-
Patent number: 11408322Abstract: A method and a sensor for detecting or measuring at least one specific component among a plurality of components present in a gaseous or liquid mixture by a sensor having at least one capturing cell with a high-electron mobility transistor including a source and a drain with a grid inserted between the source and the drain, a voltage being applied between the source and the drain, and a current intensity in the capturing cell being recorded. The voltage between the source and the drain is controlled, which varies the intensity of the current, the voltage being controlled according to a voltage model predetermined by experience in order to provide a profile with an intensity which is characteristic of said at least one specific component.Type: GrantFiled: October 16, 2017Date of Patent: August 9, 2022Assignees: PSA AUTOMOBILES SA, GEORGIA TECH LORRAINE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Vincent Aubry, Abdallah Ougazzaden, Jean-Paul Salvestini, Paul Voss, Yacine Halfaya, Chris Bishop
-
Patent number: 11408121Abstract: The invention relates to a method for the coating of a textile material, said method comprising the following steps: d) providing a coating composition comprising an aqueous solvent and an organosilicon precursor; e) impregnating the textile material with the coating composition by means of pad finishing; f) drying the impregnated textile material; characterized in that the coating composition contains no polycarboxylic acid or catalyst.Type: GrantFiled: October 13, 2017Date of Patent: August 9, 2022Assignees: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS—, SAFRAN ELECTRONICS & DEFENSE, EUROPROTECT FRANCE SAInventors: Thu-Hoa Tran-Thi, Eva Grinenval, Philippe Charton, Franck Tirard, Sebastien Chatard
-
Patent number: 11407741Abstract: The present invention relates to a compound of formula (I): wherein P1, P3, P4 and P5 are amino acid residues or amino acid like structures. The invention also relates to a compound of formula (I) for its use as a Caspase-2 inhibitor and for its therapeutical use. It also concerns the use of a compound of formula (I) as activity base probe to selectively detect Caspase-2 activity.Type: GrantFiled: September 26, 2018Date of Patent: August 9, 2022Assignees: UNIVERSITE DE PARIS, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Etienne Jacotot, Elodie Bosc
-
Publication number: 20220243312Abstract: The invention concerns a method for manufacturing an aircraft part, the part comprising a monocrystalline nickel-based superalloy substrate, the method consecutively implementing the steps of moulding the part at a moulding temperature greater than the melting temperature of the superalloy, and cooling the part, such that the monocrystalline superalloy has a ? phase and a ? phase, solution heat treatment of the part at a first temperature between the solves temperature of the ?? phase and the melting temperature of the superalloy, homogenising the crystalline structure or the part, cooling the part to ambient temperature, first tempering and second tempering.Type: ApplicationFiled: June 26, 2020Publication date: August 4, 2022Applicants: Safran Aircraft Engines, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), ECOLE NATIONALE SUPERIEURE DE MECANIQUE ET D'AEROTECHNIQUE DE POITIERS, UNIVERSITE DE POITIERSInventors: Satoshi UTADA, Joël DELAUTRE, Sarah HAMADI, Jonathan CORMIER, Patrick VILLECHAISE, Jérémy RAME
-
Publication number: 20220244171Abstract: The invention provides for methods and systems involving the measurement of values of one or several characterizing parameters representative of the kinetics of an assay chemical reaction, including providing a calibration tool (26) comprising a reaction chamber (28); for a given set of defining features, performing a series of calibration experiments under different sets of calibration values of at least one operating parameter, providing a digital calibration model representative of the kinetics of the assay chemical reaction in the calibration tool, where the assay digital calibration model comprises one or several characterizing parameters, the values of which have a dependency on the given set of defining features used for the calibration experiments; fitting, by computation, the values of the characterizing parameters for the given set of defining features, based on the series of calibration experiment results, wherein the reaction chamber (28) is a stirred-tank reactor.Type: ApplicationFiled: May 22, 2019Publication date: August 4, 2022Applicants: BIOMÉRIEUX, UNIVERSITE CLAUDE BERNARD LYON I, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Laurent DRAZEK, Christian JALLUT, Isabelle PITAULT, Maëlenn ROBIN, Mélaz TAYAKOUT-FAYOLLE
-
Publication number: 20220242739Abstract: A method for preparing a monolithic nanoporous silicate sol-gel material for modulating the pore size distribution for one single starting composition without the addition of a structuring agent. The method includes the following steps: a) synthesising a gel from at least one organosilylated precursor, the synthesis being carried out in an aqueous medium, optionally including an organic solvent and without a structuring agent, and b) drying the gel obtained in step a) at a temperature between 10° C. and 70° C., preferably between 15° C. and 55° C. and more preferably between 20° C. and 40° C., in a gas flow in a drying chamber to obtain a monolithic nanoporous silicate sol-gel material and a residual relative humidity in the drying chamber of between 0.1 and 20%, preferably between 0.5 and 10% and more preferably about 5%.Type: ApplicationFiled: October 4, 2019Publication date: August 4, 2022Applicants: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS -, ECOLE NATIONALE SUPERIEURE MINES-TELECOM LILLE-DOUAIInventors: Clarisse TRAN, Thu-Hoa TRAN-THI, Sabine CRUNAIRE, Jean-Luc WOJKIEWICZ